Wu Yiling, entrepreneur, doctor, academician of China Academy of Engineering. He was born in a family of traditional Chinese medicine. During the SARS period in 2003, he developed Lianhua Qingwen Capsule according to his collateral disease theory.
In May, 2004, Lianhua Qingwen was approved for production and marketing, and became the exclusive patent Chinese medicine of Yiling Pharmaceutical. However, the drug description of Lianhua Qingwen at that time showed that this drug was mainly used for influenza.
After SARS, in many influenza cases, such as H 1N 1, H7N9, Lianhua Qingwen repeatedly went out of the circle. During the period of influenza A (H 1N 1), Lianhua Qingwen is recommended as a Chinese medicine treatment scheme. In this year, Lianhua's pesticidal sales increased greatly, from 65.438+0.76 billion tablets in the previous year to 65.438+0.382 billion tablets.
During the COVID-19 epidemic, Lianhua Qingwen became a "world network celebrity" product. Lianhua Qingwen relies on its own efforts to carry half of the cold medicine and directly surpass Shuanghuanglian.
How to do self-prevention and control during the epidemic?
Wash your hands frequently and maintain good respiratory hygiene habits. Wash your hands with soap or hand sanitizer and tap water, and wipe your hands with disposable paper towels or clean towels.
Wash your hands immediately after contact with respiratory secretions (such as sneezing). Maintain good respiratory hygiene habits. When coughing or sneezing, cover your mouth and nose with paper towels and towels. Wash your hands after coughing or sneezing, and avoid touching your eyes, nose or mouth.